• Henriette Farkas, Kinga Viktória Kőhalmi, Nóra Veszeli, Ferenc Tóth, and Lilian Varga.
• Hungarian Angioedema Center, Third Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
• J. Obstet. Gynaecol. Res. 2016 Aug 1; 42 (8): 1026-8.

AbstractHereditary angioedema resulting from C1-inhibitor deficiency (C1-INH-HAE) is a rare, autosomal dominant disorder, characterized by recurrent attacks of edema formation. The management of pregnant patients with C1-INH-HAE is often a challenge for the physician. There is limited experience with novel therapies. Plasma-derived nanofiltered C1-INH (pnfC1-INH) is the only recommended therapeutic option during pregnancy. In our 26-year-old female patient with type II C1-INH-HAE, pregnancy was confirmed in the sixth week of gestation. During this period, the patient received the bradykinin B2-receptor antagonist, icatibant, on five occasions, as acute treatment. She experienced 119 attacks, for which she received 108 vials of pnfC1-INH during her pregnancy. The patient gave birth to a healthy baby. No side effects were detected with either treatment. No reports have been published to date on multiple dosing with icatibant during the first trimester of pregnancy. This therapy proved effective and free of maternal or fetal adverse effects. © 2016 Japan Society of Obstetrics and Gynecology.

21 keywords...

hide…